Adefovir nephrotoxicity and mitochondrial DNA depletion.
Bendele
Raymond A
RA
Richardson
Frank C
FC
D000225:Adenine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D000998:Antiviral Agents / Q000009:adverse effects*; D017326:Clinical Trials, Phase III as Topic; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004272:DNA, Mitochondrial / Q000187:drug effects*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007684:Kidney Tubules / Q000187:drug effects / Q000201:enzymology; D008928:Mitochondria / Q000187:drug effects*; D063065:Organophosphonates; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000201:enzymology / Q000473:pathology; D018119:Stavudine / Q000627:therapeutic use
D000998:Antiviral Agents; D016861:Cyclooxygenase Inhibitors; D004272:DNA, Mitochondrial; D063065:Organophosphonates; D018119:Stavudine; D000225:Adenine; C106812:adefovir dipivoxil; D006918:Hydroxyurea